Health
Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person – Manchestertimes
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nov 23, 2020–
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nov 23, 2020–
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved…
-
Noosa News17 hours agoReubhan Ralph identified as man behind terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
General16 hours agoPolice say new leads being pursued after baby’s body found in Alexander Heights stormwater drain
-
General23 hours agoQueensland announced as 2027 Women’s Softball World Cup host in first Australian event since 1965
-
General19 hours agoMan dies at shopping centre car park at Charlestown following reports of assault